Spectral AI, Inc.

Spectral AI, Inc. is a Dallas-based predictive artificial intelligence (AI) company focused on medical diagnostics. Its core mission is to revolutionize wound care management by providing faster and more accurate treatment decisions through its proprietary DeepView® Wound Diagnostics System, aiming to "See the Unknown"® in tissue health. The company's headquarters are located at 2515 McKinney Avenue, Suite 1000, Dallas, TX 75201, United States.

The company's primary product is the DeepView® System, which utilizes proprietary AI algorithms and multi-spectral imaging technology to objectively distinguish between fully damaged, partially damaged, and healthy human tissue. This system delivers a binary prediction on a wound's capacity to heal, or not heal, by a specified future time point, providing clinicians with immediate, data-driven assessments. Spectral AI initially focuses on applications for burn indications and diabetic foot ulcers (DFU), with plans for expansion into other clinical areas. The company's business model includes both a software-as-a-service (SaaS) component for licensing and algorithmic updates, and the imaging device itself.

Spectral AI is a publicly traded company on NASDAQ under the ticker MDAI. Vincent S. Capone was appointed Chief Executive Officer effective February 9, 2026, with Dr. J. Michael DiMaio serving as Chairman of the Board. David McGuire was named Chief Financial Officer, effective May 4, 2026. The DeepView® System received FDA Breakthrough Device Designation in 2018, and the company submitted a De Novo request to the FDA for the system in June 2025, marking a significant step towards commercialization. In March 2026, Spectral AI was awarded an additional $31.7 million in BARDA funding, contributing to a total of $54.9 million committed to date under a contract potentially valued up to $150 million. The company was also recognized on TIME's list of World's Top HealthTech companies in 2025 and received the Small Business Innovator Award in April 2026.